The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...

with chemotherapy (cisplatin/carboplatin and pemetrexed). BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations ...

A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients (pts)with 1 st line non-squamous NSCLC.

The most common reason for cisplatin-ineligibility is renal function impairment. Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min, as ...